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Data on body size and postmenopausal breast cancer in Hispanic and African American women are inconsistent,
possibly due to the influence of modifying factors. We examined associations between adiposity and risk of breast
cancer defined by hormone receptor status in a population-based case-control study conducted from 1995–2004 in
the San Francisco Bay Area. Multivariate adjusted odds ratios and 95% confidence intervals were calculated using
unconditional logistic regression. Associations with body size were limited to women not currently using
menopausal hormone therapy (801 cases, 1336 controls). High young-adult body mass index (BMI) was inversely
associated with postmenopausal breast cancer risk, regardless of hormone receptor status, whereas high current
BMI and high adult weight gain were associated with two-fold increased risk of estrogen receptor and
progesterone receptor positive breast cancer, but only in women with a low young-adult BMI (≤22.4 kg/m2) or
those with ≥15 years since menopause. Odds ratios were stronger among non-Hispanic Whites than Hispanics and
African Americans. Waist circumference and waist-to-height ratio increased breast cancer risk in Hispanics and
African Americans only, independent of BMI. These findings emphasize the importance of considering tumor
hormone receptor status and other modifying factors in studies of racially/ethnically diverse populations.
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Obesity has long been recognized as a risk factor for
postmenopausal breast cancer (BC) in studies of primarily
non-Hispanic White (NHW) women (World Cancer
Research Fund / American Institute for Cancer Research
2007). Only three studies in Hispanics (Wenten et al.
2002; Slattery et al. 2007; White et al. 2012) and eight
studies in African Americans (AA) (White et al. 2012;
Austin et al. 1979; Schatzkin et al. 1987; Adams-Campbell
et al. 1996; Hall et al. 2000; Zhu et al. 2005; Palmer et al.
2007; Berstad et al. 2010) examined the relation between
obesity and postmenopausal BC risk, and some of their
findings contradict those reported for NHW women,
suggesting differences in effects by racial/ethnic groups* Correspondence: esther.john@cpic.org
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in any medium, provided the original work is p(Slattery et al. 2007; Sexton et al. 2011). In NHWs, BC risk
is increased by 3-5% both per 2 kg/m2 increase in body
mass index (BMI) and per 5 kg of weight gain (World
Cancer Research Fund / American Institute for Cancer
Research 2007). Young-adult obesity, on the other hand,
has been associated with reduced postmenopausal BC
risk, both in cohort (Barnes-Josiah et al. 1995; Huang
et al. 1997; Morimoto et al. 2002; Ahn et al. 2007) and
case–control (Berstad et al. 2010; Chu et al. 1991; Brinton &
Swanson 1992; Magnusson et al. 1998) studies. A number
of factors appear to modify the relation with body size.
Increased risks associated with BMI and weight gain may
be limited to women with a low young-adult BMI (Chu
et al. 1991; Canchola et al. 2012). Stronger associations
with body size have been found in women with estrogen
receptor and progesterone receptor positive (ER+PR+) BC
(Potter et al. 1995; Huang et al. 2000; Colditz et al. 2004;
Suzuki et al. 2009), those not using menopausal hormone
therapy (HT) (Morimoto et al. 2002; Friedenreich 2001;
Feigelson et al. 2004), or with longer time sinceOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Macinnis et al. 2004). Data on abdominal obesity and BC
risk in postmenopausal women are also inconsistent
(World Cancer Research Fund / American Institute for
Cancer Research 2007) and uncertainties remain whether
associations are independent of overall obesity or differ by
race/ethnicity.
We report on the relation between overall and abdominal
adiposity and risk of postmenopausal BC defined by
hormone receptor status in a multiethnic population, and
the role of modifying factors.
Materials and methods
Study population
The San Francisco Bay Area Breast Cancer Study, a
population-based case-control study (John et al. 2003;
John et al. 2005), identified 17,581 women aged 35–79
years with newly diagnosed invasive BC through the Greater
Bay Area Cancer Registry. Following telephone screening
on study eligibility (83% participation), 2,571 cases were
selected (all Hispanics diagnosed from 1995–2002, all
AAs diagnosed from 1995–1999, and a 10% random sample
of NHWs diagnosed from 1995–1999). An in-person
interview was completed by 2,258 (88%) cases, including
1,119 (89%) Hispanics, 543 (87%) AAs, and 596 (86%)
NHWs.
Population controls, identified through random-digit
dialing, were frequency-matched on race/ethnicity and
5-year age group (John et al. 2003). Of 3,170 eligible
controls, 2,706 (85%) completed the in-person interview,
including 1,462 (88%) Hispanics, 598 (82%) AAs, and
646 (83%) NHWs.
This analysis was restricted to postmenopausal women
(1,389 cases, 1,644 controls). Women were considered
postmenopausal if their periods had stopped more than
one year prior to diagnosis (cases) or selection into the
study (controls), if they reported a bilateral oophorectomy,
or if they were aged ≥55 years at the time of diagnosis/
selection and had either started hormone therapy prior to
the cessation of menses or had had a simple hysterectomy
(without oophorectomy).
Data collection
Information on adult height, weight in the reference year
(defined as the calendar year before diagnosis for cases or
before selection into the study for controls), young-adult
weight, and other BC risk factors was collected using a
structured questionnaire, administered in English or
Spanish. Young-adult weight was based on reported
weight at age 25–30 years for cases diagnosed before May
1998 and their matched controls, and on reported
weight at age 20–29 years for cases diagnosed in May
1998 or later and their matched controls. Interviewers
also took measurements of weight, height, waist and hipcircumference (described in (John et al. 2011)). Lifetime
physical activity was assessed, as described elsewhere
(John et al. 2003). Usual dietary intake and alcohol
consumption during the reference year was assessed by a
modified version of the Block food frequency questionnaire
(Block et al. 1986). Cancer registry information on ER and
PR status was available for 85% of cases. The study was
approved by the Institutional Review Board of the Cancer
Prevention Institute of California and participants provided
written informed consent.
Body size variables
Current BMI was calculated as weight (kg) divided by
height squared (m2), based on measured height at
interview (or self-reported height for 10% of cases and
9% of controls who declined height measurements)
and self-reported weight in the reference year (or measured
weight at interview for 1% of cases and 3% of controls
without self-report). BMI was classified as normal weight
(<25.0 kg/m2), overweight (25.0-29.9 kg/m2) and obese
(≥30.0 kg/m2) (WHO 2000). Underweight (BMI <18.5
kg/m2) women (9 cases, 16 controls) were grouped with
normal weight women. Young-adult BMI was based on
measured height at interview and self-reported weight
in a woman’s twenties. Adult weight gain was calculated
as the difference between self-reported young-adult
weight and weight in the reference year. Waist-to-hip
ratio (WHR) was calculated as a measure of body fat
distribution reflecting both adipose tissue and muscle
mass; waist-to-height ratio (WHtR) was calculated as a
measure of visceral adiposity independent of height,
which may more directly reflect abdominal adiposity
(Molarius & Seidell 1998). WHR, WHtR, and waist and
hip circumferences were categorized according to the
tertile distribution among controls.
Statistical analysis
Unconditional logistic regression was used to calculate
odds ratios (OR) and 95% confidence intervals (CI)
comparing cases to controls, both overall and separately
for each racial/ethnic group. Polytomous logistic regression
was used to compare ER+PR+ and ER-PR- case groups
with a common control group. For all BCs combined and
ER+PR+ BCs, multivariate analyses were adjusted for age
(continuous) and factors significantly associated with BC
risk in our study: birth place, education, first-degree family
history of BC, personal history of benign breast disease,
age at menarche, number of full-term pregnancies, age at
first full-term pregnancy, lifetime breast-feeding, average
lifetime physical activity, alcohol consumption, and caloric
intake, categorized as shown in the tables. For ER-PR- BCs,
analyses were adjusted for age, birth place, age at me-
narche, and lifetime breast-feeding. Analyses of all BCs
combined were also adjusted for race/ethnicity. Analyses
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mutually adjusted for each other. Linear trends were
assessed across ordinal values of categorical variables.
Significant differences in ORs between groups were tested
using the Wald statistic P value. Two-sided P values
are reported for tests of trend and interaction, with
P values <0.05 considered statistically significant.
We assessed associations with current BMI and weight
change within strata defined by median young-adult
BMI (≤22.4 kg/m2, >22.4 kg/m2), median time since
menopause (<15, ≥15 years), and, in analyses of abdominal
adiposity, by current BMI (<25.0 kg/m2, ≥25.0 kg/m2).
Primary analyses were restricted to women not currently
using menopausal HT, as previous studies have found no
associations with body size among current HT users
(Huang et al. 1997; Morimoto et al. 2002). Current HT use
was defined as starting HT prior to the year of diagnosis/
selection and reported use during the year of diagnosis/
selection. All other women were classified as non-current
HT users. Time since menopause was calculated as the
difference between age at menopause and age at diagnosis/
selection. Age at menopause was based on self-report
for women with natural menopause and age at bilateral
oophorectomy for women with surgical menopause.
The final analysis was based on 2,884 postmenopausal
women (1,316 cases, 1,568 controls) after excluding 34
cases and 50 controls with missing information on
confounding variables and 39 cases and 26 controls with
unreliable caloric intake (<600 kcal/day or >5,000 kcal/day).
Statistical analyses were conducted using SAS version 9.3
software (SAS Institute, Inc., Cary, North Carolina).
Results
Cases were more likely than controls to be U.S.-born, have
a first-degree family history of BC, a personal history of
benign breast disease, higher education, earlier menarche,
fewer full-term pregnancies, a shorter duration of breast-
feeding, lower lifetime physical activity, and higher alcohol
consumption (Table 1).
Body size characteristics differed by race/ethnicity
(Table 2). Among controls, the proportion of currently
obese women (BMI ≥30.0 kg/m2) was higher in AAs and
Hispanics than in NHWs. High young-adult BMI was
twice as common in Hispanics as in NHWs, whereas the
proportion of women with high weight gain was similar
in the two groups. The prevalence of high weight gain,
large waist and hip circumferences, and high WHR was
lowest in NHWs, intermediate in Hispanics, and more
than twice as high in AAs than in NHWs.
For women not currently using HT, associations with
current BMI and adult weight gain were limited to those
with ER+PR+ tumors, although after adjustment for
weight gain, no association remained with current BMI
(Table 3). The positive association with weight gain wasnot altered by adjustment for current BMI (Table 3) or
young-adult BMI (data not shown), and was largely
driven by the increased risk found for NHW women.
Young-adult BMI was associated with reduced risk of
postmenopausal BC, with similar results for BC overall
(>23.7 vs. ≤21.2 kg/m2: OR = 0.68, 95% CI:0.54-0.86,
Ptrend < 0.01) and ER+PR+ BC (>23.7 vs. ≤21.2 kg/m
2:
OR = 0.73, 95% CI:0.54-0.98, Ptrend = 0.04). Inverse
associations, however, were found only among Hispanic
and NHW women.
Young-adult BMI was an important modifying factor
(Table 4). For ER+PR+ BC, associations with high BMI
(OR = 1.97, Ptrend = 0.01) and high weight gain (OR = 1.71,
Ptrend = 0.03) were limited to women with a young-adult
BMI ≤22.4 kg/m2. No increased risks were found among
women with both high young-adult BMI and high
current BMI. Associations were also influenced by time
since menopause. High weight gain was associated with
two-fold increased risks of BC overall (OR = 2.71, 95%
CI:1.29-5.69, Ptrend = 0.01) and ER+PR+ BC (OR = 2.47,
95% CI:1.03-5.94, Ptrend = 0.03) only in women who had
experienced menopause ≥15 years ago. Similarly, the
inverse association of young-adult BMI with BC risk
overall was seen only in women with ≥15 years since
menopause (>23.7 vs. ≤21.2 kg/m2: OR = 0.59, 95%
CI:0.41-0.85, Ptrend < 0.01).
Waist circumference was associated with ER+PR+ BC
in Hispanics (Ptrend = 0.01) and AAs (Ptrend = 0.05) only,
with two- to three-fold increased ORs for large waist
size that were independent of current BMI (Table 5).
Associations were slightly stronger for ER+PR+ disease
than BC overall. Large hip circumference was associated
with elevated ORs in Hispanics and NHWs, with a
significant trend in Hispanics (Ptrend = 0.01). There was
no association with WHR (data not shown). High WHtR
was associated with elevated ORs in Hispanics and AAs,
with a significant trend in Hispanics (Ptrend = 0.01). For
waist and hip circumferences and WHtR, associations
did not vary by time since menopause (data not shown).
Considering the joint effects of abdominal adiposity and
overall adiposity (Table 6), we found that large waist
circumference was associated with increased BC risk
only in women with a BMI <25 kg/m2. A similar pattern
was seen for WHtR. For ER+PR+ disease, ORs were
elevated, regardless of BMI, but significant only in
women with a BMI ≥25 kg/m2.
For ER-PR- BC, there were no associations with
current BMI and weight gain, whereas a strong inverse
association was found with young-adult BMI (>23.7
vs. ≤21.2 kg/m2: OR = 0.61, 95% CI:0.38-0.97, Ptrend = 0.04)
(Table 7). Modest positive associations with waist and
hip circumferences were strengthened after adjustment
for current BMI (Ptrend = 0.07 and 0.01, respectively).
Sample sizes of ER-PR- cases were too small for
Table 1 Characteristics of postmenopausal cases and controls
Cases (n = 1,316) Controls (n = 1,568) P value
n %a n %a
Age (years)
35–44 20 2 25 2
45–54 199 15 260 17
55–64 531 40 625 40
65–74 407 31 509 33
≥75 159 12 149 10
Race/ethnicity
Hispanic 614 47 804 51
Non-Hispanic White 389 30 399 26







Menopausal hormone therapy use <0.01
Never 517 39 644 41
Former 284 22 692 44
Current 498 38 214 14
Missing 17 1 18 1
Place of birth <0.01
U.S.-bornb 1,014 77 1,036 66
Foreign-born 302 23 532 34
Education (years) <0.01
Some high school or less 398 30 600 38
High school or vocational/technical school graduate 373 28 426 27
Some college 297 23 297 19
College graduate 248 19 245 16
Family history of breast cancer in first-degree relatives <0.01
No 1,089 83 1,371 87
Yes 227 17 197 13
Personal history of biopsy-confirmed benign breast disease 0.01
No 1,016 77 1,274 81
Yes 300 23 294 19
Age at menarche <0.01
≤11 304 23 327 21
12 349 27 356 23
13 319 24 387 25
≥14 344 26 498 32
Parity <0.01
Nulliparous 169 13 145 9
Parous 1,147 87 1,423 91
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Table 1 Characteristics of postmenopausal cases and controls (Continued)
Number of full-term pregnancies, parous women <0.01
1 162 14 177 12
2 309 27 303 21
3 263 23 349 25
≥4 413 36 594 42
Age at first full-term pregnancy (years), parous women <0.01
≤19 302 26 415 29
20–24 462 40 564 40
25–29 235 21 298 21
≥30 148 13 146 10
Lifetime breast-feeding (months), parous women <0.01
0 541 47 547 38
≤ 6 250 22 294 21
7–12 97 8 148 10
13–24 126 11 184 13
≥25 133 12 250 18
Lifetime physical activityc (hours/week) 0.04
≤ 6.9 376 29 391 25
7.0-14.1 342 26 390 25
14.2-25.4 291 22 403 26
≥25.5 307 23 384 25
Alcohol consumptiond,e (g/day) <0.01
0 763 58 975 62
0.1-4.9 262 20 312 20
5.0-9.9 68 5 91 6
10.0-19.9 115 9 107 7
≥20 108 8 83 5
Total caloric intakec,d,e (kcal/day) 0.05
≤ 1362 287 22 394 25
1363–1798 343 26 385 25
1799–2435 379 29 398 25
≥2436 307 23 391 25
Abbreviations: ER-, estrogen receptor–negative; ER+, estrogen receptor–positive; PR-, progesterone receptor–negative; PR+, progesterone receptor–positive.
a Percentages may not add up to 100% due to rounding.
b U.S.-born includes 43 cases and 34 controls born in westernized countries such as Canada, Europe, Australia, or New Zealand.
c Quartiles among all postmenopausal controls.
d In reference year.
e Excludes 39 cases and 26 controls whose total caloric intake was <600 kcal/day or >5,000 kcal/day.
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79 Hispanics).
Among women currently using HT (289 cases, 498
controls), there was no evidence of significant associations
between any of the body size measures examined and BC
risk overall or ER+PR+ disease (data not shown).
Discussion
In postmenopausal women not currently using HT, weight
gain was positively associated with risk of ER+PR+ BCand was a stronger predictor of risk than current BMI.
The highest elevations in risks were found in subgroups of
women with a low young-adult BMI or ≥15 years since
menopause. Young-adult obesity was associated with
reduced BC risk. High waist circumference and WHtR
were associated with increased BC risk, independent
of current BMI. Associations with weight gain and
young-adult BMI were stronger for NHWs than Hispanics
and AAs, whereas associations with waist and WHtR were
present only in Hispanic and AA women.








n %b n %b n %b
Current BMI (kg/m2) c * †
<25.0 147 18 80 22 185 47
25.0-29.9 310 39 124 34 116 29
≥30.0 342 43 159 44 97 24
Young-adult BMI (kg/m2) d,e * ‡
Q1: ≤20.6 125 17 116 32 130 33
Q2: 20.7-22.4 170 23 83 23 118 30
Q3: 22.5-24.7 210 29 84 23 76 19
Q4: >24.7 225 31 77 21 69 18
Weight gain (kg) f * † ‡
Stable g 80 11 31 9 65 18
Gain, 3.0-9.9 176 25 66 19 113 31
Gain, 10.0-19.9 234 33 91 26 96 26
Gain, 20.0-29.9 142 20 83 24 63 17
Gain, ≥30.0 74 11 76 22 34 9
Waist (cm) d * † ‡
Q1: ≤ 82.3 170 22 41 14 150 43
Q2: 82.4-90.5 211 27 65 22 77 22
Q3: 90.6-99.8 196 25 90 30 67 19
Q4: >99.8 195 25 102 34 57 16
Hip (cm) d * † ‡
Q1: ≤ 100.5 206 27 48 16 103 29
Q2: 100.6-107.5 186 24 60 20 107 31
Q3: 107.6-116.2 183 24 85 29 87 25
Q4: >116.2 196 25 105 35 54 15
Waist-to-hip ratio (WHR) d * † ‡
Q1: ≤ 0.79 172 22 52 18 163 46
Q2: 0.80-0.84 224 29 70 24 83 24
Q3: 0.85-0.88 190 25 83 28 53 15
Q4: >0.88 185 24 92 31 52 15
Waist-to-height ratio (WHtR) d * †
Q1: ≤ 0.52 138 18 56 19 162 46
Q2: 0.53-0.58 195 25 78 26 82 23
Q3: 0.59-0.64 216 28 81 27 58 17
Q4: >0.64 223 29 83 28 49 14
Abbreviation: BMI, body mass index.
a Chi-square test for the difference between race/ethnicity; * = P <0.05 between non-Hispanic Whites and Hispanics; † = P <0.05 between non-Hispanic Whites and
African Americans; ‡ = P <0.05 between Hispanics and African Americans.
b Percentages may not add up to 100% due to rounding.
c Based on self-reported adult weight and measured height at interview (if not available, then based on measured weight at interview and/or self-reported
adult height).
d Based on quartiles among all postmenopausal controls.
e Based on self-reported young-adult weight and measured height at interview (or self-reported adult height when measured height not available).
f Self-reported adult weight (or measured weight at interview if self-reported weight not available) minus self-reported young-adult weight; excludes 64 controls
who lost >3 kg of weight.
g Stable weight defined as +/− 3 kg.
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Table 3 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicity a and estrogen receptor
and progesterone receptor status
All race/ethnicities Hispanics African Americans Non-Hispanic Whites

















Current BMI (kg/m2) d
<25.0 208 329 1.0 81 119 1.0 51 70 1.0 76 140 1.0
25.0-29.9 278 476 0.95 0.74-1.21 133 273 0.78 0.54-1.14 90 106 1.19 0.74-1.94 55 97 0.90 0.56-1.43
≥30.0 312 523 0.94 0.74-1.20 161 312 0.77 0.53-1.12 101 137 1.07 0.66-1.73 50 74 1.19 0.72-1.99
P trend = 0.64 P trend = 0.24 P trend = 0.88 P trend = 0.58
Current BMI (kg/m2) –adjusted for weight
gain d,e
<25.0 1.0 1.0 1.0 1.0
25.0-29.9 0.90 0.67-1.20 0.80 0.52-1.25 1.25 0.70-2.26 0.63 0.34-1.16
≥30.0 0.79 0.56-1.13 0.73 0.43-1.24 1.15 0.57-2.30 0.52 0.22-1.22
P trend = 0.75 P trend = 0.26 P trend = 0.77 P trend = 0.11
Young-adult BMI (kg/m2) f,g
T1: ≤21.2 286 402 1.0 109 161 1.0 93 122 1.0 84 119 1.0
T2: 21.3-23.7 259 411 0.87 0.69-1.09 122 209 0.85 0.60-1.20 77 90 1.17 0.76-1.79 60 112 0.65 0.41-1.02
T3: >23.7 216 445 0.68 0.54-0.86 115 272 0.63 0.45-0.90 67 98 0.93 0.59-1.45 34 75 0.52 0.30-0.90
P trend < 0.01 P trend = 0.01 P trend = 0.80 P trend = 0.01
Weight gain (kg) h,i 78 140
Stable j 180 291 1.0 36 65 1.0 18 26 1.0 24 49 1.0
Gain, 3.0-9.9 217 376 1.15 0.82-1.63 82 149 1.05 0.63-1.76 50 55 1.27 0.59-2.73 48 87 1.27 0.67-2.43
Gain, 10.0-19.9 142 247 1.06 0.76-1.48 101 217 0.88 0.54-1.45 68 80 1.18 0.57-2.44 48 79 1.36 0.71-2.62
Gain, 20.0-29.9 111 154 1.03 0.72-1.48 71 125 1.04 0.61-1.78 44 72 0.91 0.43-1.93 27 50 1.19 0.57-2.48
Gain, ≥30.0 1.19 0.81-1.75 38 67 0.91 0.50-1.66 51 64 1.13 0.54-2.39 22 23 2.63 1.12-6.19














Table 3 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicity a and estrogen receptor
and progesterone receptor status (Continued)
Weight gain (kg) – adjusted for current
BMI h,i,k
Stable j 1.0 1.0 1.0 1.0
Gain, 3.0-9.9 1.17 0.83-1.65 1.07 0.64-1.80 1.17 0.54-2.56 1.38 0.71-2.67
Gain, 10.0-19.9 1.14 0.79-1.65 1.00 0.58-1.70 1.00 0.45-2.24 1.92 0.89-4.15
Gain, 20.0-29.9 1.17 0.77-1.78 1.22 0.66-2.25 0.76 0.32-1.85 1.94 0.75-5.03
Gain, ≥30.0 1.41 0.88-2.26 1.12 0.55-2.27 0.99 0.39-2.49 4.70 1.48-14.97
P trend = 0.24 P trend = 0.67 P trend = 0.68 P trend = 0.02

















Current BMI (kg/m2) d
<25.0 98 329 1.0 34 119 1.0 19 70 1.0 45 140 1.0
25.0-29.9 141 476 1.09 0.80-1.49 60 273 0.90 0.54-1.49 44 106 1.76 0.89-3.47 37 97 1.06 0.61-1.85
≥30.0 175 523 1.30 0.95-1.78 96 312 1.23 0.75-2.01 45 137 1.46 0.74-2.89 34 74 1.39 0.76-2.55
P trend = 0.09 P trend = 0.22 P trend = 0.40 P trend = 0.30
Current BMI (kg/m2) – adjusted for weight
gain d,e
<25.0 1.0 1.0 1.0 1.0
25.0-29.9 1.06 0.73-1.54 1.01 0.56-1.84 1.77 0.78-4.06 0.74 0.35-1.56
≥30.0 1.01 0.64-1.60 1.17 0.58-2.35 1.29 0.48-3.48 0.64 0.23-1.76
P trend = 0.99 P trend = 0.62 P trend = 0.78 P trend = 0.37
Young-adult BMI (kg/m2) f,g
T1: ≤21.2 147 402 1.0 51 161 1.0 45 122 1.0 51 119 1.0
T2: 21.3-23.7 133 411 0.87 0.65-1.15 58 209 0.87 0.55-1.37 35 90 1.23 0.69-2.20 40 112 0.66 0.38-1.15
T3: >23.7 116 445 0.73 0.54-0.98 65 272 0.80 0.51-1.25 28 98 0.73 0.39-1.36 23 75 0.52 0.27-1.00
P trend = 0.04 P trend = 0.33 P trend = 0.39 P trend = 0.04
Weight gain (kg) h,l
Stable j 44 140 1.0 18 65 1.0 9 26 1.0 17 49 1.0
Gain, 3.0-9.9 79 291 0.94 0.61-1.46 32 149 0.80 0.41-1.58 20 55 1.11 0.40-3.14 27 87 1.02 0.48-2.18
Gain, 10.0-19.9 114 376 1.07 0.71-1.62 55 217 1.00 0.53-1.88 26 80 0.96 0.36-2.57 33 79 1.48 0.70-3.15
Gain, 20.0-29.9 77 247 1.12 0.72-1.74 34 125 1.02 0.52-2.03 25 72 1.19 0.44-3.18 18 50 1.29 0.55-3.04
Gain, ≥30.0 67 154 1.53 0.96-2.45 29 67 1.43 0.70-2.94 24 64 1.27 0.47-3.42 14 23 2.56 0.95-6.88














Table 3 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicity a and estrogen receptor
and progesterone receptor status (Continued)
Weight gain (kg) – adjusted for current
BMI h,k,l
Stable j 1.0 1.0 1.0 1.0
Gain, 3.0-9.9 0.93 0.60-1.44 0.81 0.41-1.59 0.92 0.31-2.67 1.09 0.50-2.38
Gain, 10.0-19.9 1.04 0.66-1.65 0.96 0.49-1.89 0.67 0.22-2.04 1.90 0.77-4.73
Gain, 20.0-29.9 1.10 0.65-1.86 0.93 0.43-2.05 0.85 0.26-2.77 1.80 0.58-5.63
Gain, ≥30.0 1.53 0.85-2.73 1.29 0.55-3.01 1.02 0.29-3.58 3.82 0.99-14.71
P trend = 0.13 P trend = 0.48 P trend = 0.90 P trend = 0.06
Abbreviations: BMI, body mass index; CI, confidence interval; ER+, estrogen receptor–positive; OR, odds ratio; PR+, progesterone receptor–positive.
a All P values for interaction by race/ethnicity were >0.05.
b Adjusted for age (years, continuous), race/ethnicity (non-Hispanic White, African American, Hispanic), place of birth (U.S.-born, foreign-born), education (some high school or less, high school or vocational/technical
school graduate, some college, college graduate), first-degree family history of breast cancer (no, yes), personal history of biopsy-confirmed benign breast disease (no, yes), age at menarche (≤11, 12, 13, ≥14 years),
number of full-term pregnancies (nulliparous, 1, 2, 3, ≥4), age at first full-term pregnancy (nulliparous, ≤19, 20–24, 25–29, ≥30 years), lifetime breast-feeding (nulliparous, 0, ≤6, 7–12, 13–24, ≥25 months), lifetime
physical activity (quartiles, hours/week), alcohol consumption in reference year (0, 0.1-4.9, 5–9.9, 10–19.9, ≥20 g/day), and total caloric intake (quartiles, kcal/day).
c Not adjusted for race/ethnicity.
d Based on self-reported weight and measured height at interview (if not available, then based on measured weight at interview and/or self-reported height).
e Adjusted for above variables, and weight gain.
f Based on tertiles among all postmenopausal controls.
g Based on self-reported young-adult weight and measured height at interview (or self-reported adult height when measured height not available).
h Self-reported weight (or measured weight at interview if self-reported weight not available) minus self-reported young-adult weight.
i Excludes 34 cases and 55 controls who lost >3 kg of weight.
j Stable weight defined as +/− 3 kg.
k Adjusted for above variables, and current BMI.














Table 4 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by young-adult BMI and time since menopause
Young-adult BMI Young-adult BMI
≤22.4 kg/m2 >22.4 kg/m2
All breast cancer Cases (n = 413) Controls (n = 614) ORa 95% CI Cases (n = 348) Controls (n = 644) ORa 95% CI P interaction
Current BMI (kg/m2) b 0.01
<25.0 167 243 1.0 38 77 1.0
25.0-29.9 131 232 0.77 0.56-1.06 136 217 1.28 0.80-2.05
≥30.0 115 138 1.22 0.86-1.74 174 350 0.92 0.58-1.45
P trend = 0.42 P trend = 0.19
Weight gain (kg) c,d 0.12
Stable e 35 52 1.0 43 87 1.0
Gain, 3.0-9.9 106 142 1.20 0.71-2.03 74 148 1.03 0.64-1.66
Gain, 10.0-19.9 109 198 0.82 0.49-1.38 108 176 1.26 0.80-1.99
Gain, 20.0-29.9 90 126 1.11 0.65-1.91 51 120 0.81 0.48-1.36
Gain, ≥30.0 67 84 1.14 0.64-2.05 44 69 1.08 0.62-1.90
P trend = 0.84 P trend = 0.81
ER+PR+ breast cancer Cases (n = 209) Controls (n = 614) ORa 95% CI Cases (n = 187) Controls (n = 644) ORa 95% CI P interaction
Current BMI (kg/m2) b 0.01
<25.0 77 243 1.0 19 77 1.0
25.0-29.9 63 232 0.87 0.57-1.32 74 217 1.42 0.78-2.59
≥30.0 69 138 1.97 1.26-3.09 94 350 1.10 0.61-1.98
P trend = 0.01 P trend = 0.69
Weight gain (kg) c,f 0.08
Stable e 20 52 1.0 24 87 1.0
Gain, 3.0-9.9 42 142 0.97 0.50-1.88 37 148 0.99 0.54-1.80
Gain, 10.0-19.9 52 198 0.83 0.43-1.59 62 176 1.44 0.82-2.54
Gain, 20.0-29.9 50 126 1.35 0.69-2.64 27 120 0.88 0.46-1.69
Gain, ≥30.0 41 84 1.71 0.83-3.52 26 69 1.48 0.75-2.94
P trend = 0.03 P trend = 0.42
<15 Years Since Menopauseg ≥15 Years Since Menopauseg
All breast cancer Cases (n = 335) Controls (n = 552) ORa 95% CI Cases (n = 352) Controls (n = 576) ORa 95% CI P interaction
Current BMI (kg/m2) b 0.09
<25.0 98 134 1.0 82 138 1.0
25.0-29.9 115 187 0.85 0.57-1.26 126 229 0.97 0.67-1.41
≥30.0 120 227 0.70 0.47-1.03 143 205 1.24 0.84-1.81














Table 4 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by young-adult BMI and time since menopause
(Continued)
Current BMI (kg/m2) –adjusted for weight gain b,h 0.31
<25.0 1.0 1.0
25.0-29.9 0.89 0.56-1.42 0.73 0.46-1.15
≥30.0 0.85 0.47-1.51 0.68 0.39-1.18
P trend = 0.58 P trend = 0.20
Young-adult BMI (kg/m2) i,j 0.57
T1: ≤21.2 120 181 1.0 127 163 1.0
T2: 21.3-23.7 112 163 1.03 0.72-1.48 112 174 0.82 0.58-1.16
T3: >23.7 90 181 0.78 0.53-1.14 92 199 0.59 0.41-0.85
P trend = 0.22 P trend < 0.01
Weight gain (kg) c,k 0.12
Stable e 33 55 1.0 32 68 1.0
Gain, 3.0-9.9 85 116 1.13 0.65-1.96 72 133 1.29 0.76-2.20
Gain, 10.0-19.9 101 165 0.89 0.53-1.52 92 152 1.40 0.83-2.35
Gain, 20.0-29.9 52 98 0.82 0.46-1.48 66 105 1.44 0.83-2.50
Gain, ≥30.0 40 73 0.69 0.37-1.30 53 55 2.09 1.15-3.81
P trend = 0.08 P trend = 0.02
Weight gain (kg) – adjusted for current BMI c,k,l 0.12
Stable e 1.0 1.0
Gain, 3.0-9.9 1.16 0.67-2.01 1.34 0.78-2.30
Gain, 10.0-19.9 0.96 0.54-1.71 1.67 0.93-2.99
Gain, 20.0-29.9 0.91 0.46-1.82 1.77 0.92-3.38
Gain, ≥30.0 0.78 0.36-1.68 2.71 1.29-5.69
P trend = 0.40 P trend = 0.01
ER+PR+ breast cancer Cases (n = 156) Controls (n = 552) ORa 95% CI Cases (n = 201) Controls (n = 576) ORa 95% CI P interaction
Current BMI (kg/m2) b 0.45
<25.0 42 134 1.0 40 138 1.0
25.0-29.9 47 187 0.89 0.53-1.50 77 229 1.26 0.79-2.02
≥30.0 66 227 1.07 0.64-1.78 84 205 1.63 1.00-2.65
P trend = 0.71 P trend = 0.05
Current BMI (kg/m2) –adjusted for weight gain b,h 0.43
<25.0 1.0 1.0
25.0-29.9 0.97 0.52-1.81 1.15 0.64-2.07
≥30.0 1.35 0.63-2.87 0.94 0.46-1.92














Table 4 BMI and weight gain and breast cancer risk in postmenopausal women not currently using hormone therapy by yo ng-adult BMI and time since menopause
(Continued)
Young-adult BMI (kg/m2) i,j 0.76
T1: ≤21.2 56 181 1.0 67 163 1.0
T2: 21.3-23.7 49 163 1.00 0.62-1.59 66 174 0.89 0.58-1.37
T3: >23.7 45 181 0.89 0.54-1.46 58 199 0.70 0.45-1.10
P trend = 0.64 P trend = 0.12
Weight gain (kg) c,m 0.51
Stable e 16 55 1.0 22 68 1.0
Gain, 3.0-9.9 34 116 0.94 0.46-1.93 34 133 0.93 0.48-1.77
Gain, 10.0-19.9 48 165 0.98 0.49-1.94 53 152 1.25 0.68-2.30
Gain, 20.0-29.9 24 98 0.85 0.40-1.84 40 105 1.38 0.72-2.64
Gain, ≥30.0 24 73 0.99 0.45-2.17 33 55 2.32 1.15-4.69
P trend = 0.91 P trend = 0.01
Weight gain (kg) – adjusted for current BMI c,l,m 0.48
Stable e 1.0 1.0
Gain, 3.0-9.9 0.95 0.46-1.95 0.86 0.44-1.68
Gain, 10.0-19.9 0.94 0.44-1.97 1.17 0.59-2.33
Gain, 20.0-29.9 0.70 0.28-1.73 1.39 0.64-3.01
Gain, ≥30.0 0.76 0.29-1.99 2.47 1.03-5.94
P trend = 0.50 P trend = 0.03
Abbreviations: BMI, body mass index; CI, confidence interval; ER+, estrogen receptor–positive; OR, odds ratio; PR+, progesterone receptor–positive.
a Adjusted for age (years, continuous), race/ethnicity (non-Hispanic White, African American, Hispanic), place of birth (U.S.-born, foreign-born), education (some h h school or less, high school or vocational/technical
school graduate, some college, college graduate), family history of breast cancer in first-degree relatives (no, yes), personal history of biopsy-confirmed benign b ast disease (no, yes), age at menarche (≤11, 12, 13,
≥14 years), number of full-term pregnancies (nulliparous, 1, 2, 3, ≥4), age at first full-term pregnancy (nulliparous, ≤19, 20–24, 25–29, ≥30 years), lifetime breast-f ding (nulliparous, 0, ≤6, 7–12, 13–24, ≥25 months),
lifetime physical activity (quartiles, hours/week), alcohol consumption in reference year (0, 0.1-4.9, 5–9.9, 10–19.9, ≥20 g/day), and total caloric intake (quartiles, k l/day).
b Based on self-reported weight and measured height at interview (if not available, then based on measured weight at interview and/or self-reported height).
c Self-reported weight (or measured weight at interview if self-reported weight not available) minus self-reported young-adult weight.
d Excludes 34 cases and 55 controls who lost >3 kg of weight.
e Stable weight defined as +/− 3 kg.
f Excludes 15 ER+PR+ cases and 55 controls who lost >3 kg of weight.
g Among women with natural or surgical menopause only.
h Adjusted for above variables, and weight gain.
i Based on tertiles among all postmenopausal controls.
j Based on self-reported young-adult weight and measured height at interview (or self-reported adult height when measured height not available).
k Excludes 28 cases and 46 controls who lost >3 kg of weight.
l Adjusted for above variables, and current BMI.


















Table 5 Abdominal adiposity and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicitya
All race/ethnicities Hispanics African Americans Non-Hispanic Whites


















T1: ≤ 85.0 198 385 1.0 96 201 1.0 30 54 1.0 72 130 1.0
T2: 85.1-96.4 214 407 0.99 0.77-1.27 113 245 0.90 0.63-1.27 59 78 1.55 0.85-2.83 42 84 0.91 0.55-1.52
T3: >96.4 293 412 1.32 1.03-1.69 146 232 1.27 0.90-1.79 102 120 1.83 1.04-3.21 45 60 1.24 0.72-2.13
P trend = 0.02 P trend = 0.14 P trend = 0.05 P trend = 0.52
Waist (cm) – adjusted for current
BMI d,e
T1: ≤ 85.0 1.0 1.0 1.0 1.0
T2: 85.1-96.4 1.09 0.82-1.44 1.08 0.73-1.60 1.64 0.84-3.20 0.80 0.44-1.47
T3: >96.4 1.59 1.15-2.19 1.79 1.14-2.81 2.17 1.05-4.49 0.90 0.42-1.91
P trend < 0.01 P trend = 0.01 P trend = 0.04 P trend = 0.75
Hip (cm) d
T1: ≤ 102.9 194 394 1.0 105 224 1.0 39 60 1.0 50 110 1.0
T2: 103.0-112.7 230 402 1.15 0.90-1.47 119 229 1.13 0.80-1.58 54 77 1.06 0.60-1.88 57 96 1.46 0.87-2.43
T3: >112.7 281 407 1.36 1.07-1.73 131 224 1.22 0.87-1.71 98 115 1.51 0.89-2.56 52 68 1.80 1.03-3.14
P trend = 0.01 P trend = 0.26 P trend = 0.09 P trend = 0.04
Hip (cm) – adjusted for current
BMI d,e
T1: ≤ 102.9 1.0 1.0 1.0 1.0
T2: 103.0-112.7 1.27 0.97-1.66 1.34 0.92-1.94 1.04 0.54-2.00 1.58 0.90-2.79
T3: >112.7 1.66 1.20-2.30 1.64 1.05-2.58 1.68 0.82-3.42 1.88 0.86-4.10
P trend < 0.01 P trend = 0.03 P trend = 0.10 P trend = 0.09
Waist-to-height ratio d
T1: ≤ 0.54 200 372 1.0 80 153 1.0 42 70 1.0 78 149 1.0
T2: 0.55-0.61 226 410 1.05 0.81-1.35 117 254 0.88 0.61-1.28 64 85 1.42 0.82-2.45 45 71 1.27 0.76-2.12
T3: >0.61 279 422 1.27 0.98-1.64 158 271 1.13 0.78-1.62 85 97 1.74 1.02-2.96 36 54 1.16 0.65-2.06














Table 5 Abdominal adiposity and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicitya (Continued)
Waist-to-height ratio – adjusted for current
BMI d,e
T1: ≤ 0.54 1.0 1.0 1.0 1.0
T2: 0.55-0.61 1.14 0.86-1.52 1.05 0.69-1.60 1.55 0.82-2.91 1.13 0.61-2.09
T3: >0.61 1.49 1.06-2.09 1.55 0.96-2.50 2.22 1.09-4.51 0.85 0.39-1.84
P trend = 0.02 P trend = 0.05 P trend = 0.03 P trend = 0.72


















T1: ≤ 85.0 95 385 1.0 42 201 1.0 8 54 1.0 45 130 1.0
T2: 85.1-96.4 106 407 1.11 0.80-1.54 55 245 1.01 0.63-1.61 26 78 2.70 1.01-7.17 25 84 0.88 0.48-1.63
T3: >96.4 162 412 1.76 1.28-2.41 84 232 1.79 1.14-2.81 46 120 3.31 1.29-8.48 32 60 1.38 0.75-2.56
P trend < 0.01 P trend = 0.01 P trend = 0.02 P trend = 0.33
Waist (cm) – adjusted for current
BMI d,e
T1: ≤ 85.0 1.0 1.0 1.0 1.0
T2: 85.1-96.4 1.13 0.78-1.63 1.12 0.66-1.90 2.48 0.86-7.19 0.75 0.37-1.52
T3: >96.4 1.83 1.21-2.79 2.03 1.11-3.70 3.36 1.10-10.28 0.98 0.41-2.32
P trend < 0.01 P trend = 0.01 P trend = 0.05 P trend = 0.93
Hip (cm) d
T1: ≤ 102.9 92 394 1.0 46 224 1.0 17 60 1.0 29 110 1.0
T2: 103.0-112.7 118 402 1.32 0.96-1.81 56 229 1.23 0.78-1.94 23 77 1.04 0.48-2.28 39 96 1.76 0.95-3.25
T3: >112.7 153 407 1.77 1.30-2.42 79 224 1.85 1.19-2.85 40 115 1.54 0.74-3.21 34 68 2.06 1.07-3.97
P trend < 0.01 P trend = 0.01 P trend = 0.20 P trend = 0.03
Hip (cm) – adjusted for current
BMI d,e
T1: ≤ 102.9 1.0 1.0 1.0 1.0
T2: 103.0-112.7 1.36 0.96-1.93 1.38 0.83-2.28 0.77 0.31-1.88 1.81 0.92-3.56
T3: >112.7 1.85 1.22-2.81 2.12 1.17-3.84 1.18 0.45-3.08 1.96 0.78-4.91
P trend < 0.01 P trend = 0.01 P trend = 0.57 P trend = 0.12
Waist-to-height ratio d
T1: ≤ 0.54 98 372 1.0 36 153 1.0 14 70 1.0 48 149 1.0
T2: 0.55-0.61 112 410 1.15 0.83-1.59 51 254 0.88 0.53-1.46 30 85 1.94 0.86-4.35 31 71 1.44 0.79-2.65
T3: >0.61 153 422 1.61 1.16-2.23 94 271 1.63 1.02-2.62 36 97 2.19 0.99-4.82 23 54 1.14 0.59-2.23














Table 5 Abdominal adiposity and breast cancer risk in postmenopausal women not currently using hormone therapy by race/ethnicitya (Continued)
Waist-to-height ratio –adjusted for current
BMI d,e
T1: ≤ 0.54 1.0 1.0 1.0 1.0
T2: 0.55-0.61 1.13 0.77-1.64 0.97 0.55-1.73 1.75 0.72-4.26 1.19 0.58-2.48
T3: >0.61 1.55 1.00-2.39 1.83 0.97-3.47 2.19 0.81-5.93 0.74 0.30-1.85
P trend = 0.04 P trend = 0.02 P trend = 0.14 P trend = 0.62
Abbreviations: BMI, body mass index; CI, confidence interval; ER+, estrogen receptor–positive; OR, odds ratio; PR+, progesterone receptor–positive.
a All P values for interaction by race/ethnicity were >0.05.
b Adjusted for age (years, continuous), race/ethnicity (non-Hispanic White, African American, Hispanic), place of birth (U.S.-born, foreign-born), education (some high school or less, high school or vocational/technical
school graduate, some college, college graduate), first-degree family history of breast cancer (no, yes), personal history of biopsy-confirmed benign breast disease (no, yes), age at menarche (≤11, 12, 13, ≥14 years),
number of full-term pregnancies (nulliparous, 1, 2, 3, ≥4), age at first full-term pregnancy (nulliparous, ≤19, 20–24,
25–29, ≥30 years), lifetime breast-feeding (nulliparous, 0, ≤6, 7–12, 13–24, ≥25 months), lifetime physical activity (quartiles, hours/week), alcohol consumption in reference year (0, 0.1-4.9, 5–9.9, 10–19.9, ≥20 g/day),
and total caloric intake (quartiles, kcal/day).
c Adjusted for above variables, except race/ethnicity.
d Based on tertiles among all postmenopausal controls.














Table 6 Abdominal adiposity and breast cancer risk in postmenopausal women not currently using hormone therapy
by current BMI
Current BMI < 25.0kg/m2 Current BMI ≥ 25.0kg/m2
All breast cancer Cases (n=396) Controls (n=648) ORa 95% CI Cases (n=402) Controls (n=680) ORa 95% CI P interaction
Waist (cm) b
M1: ≤ 90.5 151 272 1.00 140 321 0.87 0.65-1.18 0.25
M2: > 90.5 27 26 1.90 1.05-3.44 387 585 1.21 0.93-1.57
Waist-to-height ratio b
M1: ≤ 0.58 156 276 1.00 152 310 0.93 0.69-1.24 0.93
M2: > 0.58 22 22 1.87 0.98-3.56 375 596 1.17 0.90-1.52
ER+PR+ breast cancer Cases (n=194) Controls (n=648) ORa 95% CI Cases (n=220) Controls (n=680) ORa 95% CI P interaction
Waist (cm) b
M1: ≤ 90.5 73 272 1.00 67 321 0.92 0.62-1.36 0.16
M2: > 90.5 10 26 1.53 0.69-3.39 213 585 1.55 1.11-2.17
Waist-to-height ratio b
M1: ≤ 0.58 75 276 1.00 75 310 1.02 0.70-1.50 0.47
M2: > 0.58 8 22 1.53 0.63-3.68 205 596 1.52 1.08-2.12
Abbreviations: BMI, body mass index; CI, confidence interval; ER+, estrogen receptor–positive; OR, odds ratio; PR+, progesterone receptor–positive.
a OR and 95% CI adjusted for age (years, continuous), race/ethnicity (non-Hispanic White, African American, Hispanic), place of birth (US-born, foreign-born),
education (some high school or less, high school or vocational/technical school graduate, some college, college graduate), family history of breast cancer in
first-degree relatives (no, yes), personal history of biopsy-confirmed benign breast disease (no, yes), age at menarche (≤11, 12, 13, ≥14 years), number of full-term
pregnancies (nulliparous, 1, 2, 3, ≥4), age at first full-term pregnancy (nulliparous, ≤19, 20–24, 25–29, ≥30 years), lifetime breast-feeding (nulliparous, 0, ≤6, 7–12,
13–24, ≥25 months), lifetime physical activity (quartiles, hours/week), alcohol consumption in reference year (0, 0.1-4.9, 5–9.9, 10–19.9, ≥20 g/day), and total caloric
intake (quartiles, kcal/day).
b Based on median among all postmenopausal controls.
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http://www.springerplus.com/content/2/1/239Consistent with other reports (White et al. 2012; Huang
et al. 1997; Ahn et al. 2007; Feigelson et al. 2004), we
found that weight gain was an important risk factor for
postmenopausal BC, independent of current BMI. For
current BMI no association remained after adjustment for
weight gain. In agreement with other studies (Vrieling
et al. 2010), we found that the relation with weight gain
was limited to ER+PR+ BC. Risk was increased two-fold
for currently obese women (BMI ≥30 kg/m2) who had a
young-adult BMI <22.4 kg/m2, which is in agreement with
other studies (Ahn et al. 2007; Canchola et al. 2012).
We found modest effect modification by young adult
BMI for weight gain, though some other studies did not
(Barnes-Josiah et al. 1995; Feigelson et al. 2004; van den
Brandt et al. 1997; Lahmann et al. 2005). In contrast,
BC risk was not increased in women who were obese
throughout their adult life, consistent with other (Ahn
et al. 2007; Canchola et al. 2012), but not all reports
(Barnes-Josiah et al. 1995). In agreement with other reports
(Chu et al. 1991; Magnusson et al. 1998; Macinnis et al.
2004), we found time since menopause to be another
important modifying factor, with two-fold increased
risks of ER+PR+ BC with weight gain only among
women with ≥15 years since menopause. Weight gain
during adulthood largely reflects an increase in body
fat which serves as an important source of estrogen
production in postmenopausal women (Siiteri 1987).
The role of an estrogen-related pathway is furthersupported by the observation that the associations with
BMI and weight gain are limited to ER+PR+ tumors
(Suzuki et al. 2009; Vrieling et al. 2010).
Prior findings in AA and Hispanic women for BMI are
inconsistent. In our study, OR estimates were increased
only for ER+PR+ disease and were of similar magnitude
in the three racial/ethnic groups. Two studies in AAs
reported elevated risks of ER+PR+ disease (Palmer et al.
2007; Berstad et al. 2010), and, similar to our study,
there was no evidence of an association with BMI for
BC overall. Other studies did not consider hormone
receptor status (White et al. 2012; Schatzkin et al. 1987;
Adams-Campbell et al. 1996; Hall et al. 2000; Zhu et al.
2005), and not all found a positive association with BMI
(White et al. 2012; Schatzkin et al. 1987; Zhu et al.
2005). In black women from Nigeria (Ogundiran et al.
2010; Okobia et al. 2006; Adebamowo et al. 2003) and
Barbados (Nemesure et al. 2009), no associations with
BMI were found. In Hispanic women, BMI was not
associated with BC overall (Wenten et al. 2002;
Slattery et al. 2007; White et al. 2012) and ER+ disease
(Slattery et al. 2007), even among women not using HT
(Slattery et al. 2007; White et al. 2012).
We found that high weight gain was associated with a
two-fold increased risk of ER+PR+ BC in NHW women.
In AAs and Hispanics, the associations were much weaker,
likely due to the higher prevalence of young-adult obesity
in these groups. Of three studies in AAs that reported on
Table 7 Body size and risk of ER-PR- breast cancer in postmenopausal women not currently using hormone therapy
Cases (n=135) Controls (n=1,336) ORa, 95% CI ORb 95% CI ORc 95% CI
Current BMI(kg/m2) d
<25.0 34 329 1.00 1.00
25.0-29.9 46 476 0.75 0.46-1.22 0.62 0.36-1.08
≥30.0 54 523 0.72 0.45-1.16 0.58 0.30-1.14
P trend = 0.21 P trend = 0.13
Young-adult BMI (kg/m2) e,f
T1: ≤21.2 46 402 1.00
T2: 21.3-23.7 43 411 0.82 0.52-1.29
T3: >23.7 37 445 0.61 0.38-0.97
P trend = 0.04
Weight gain (kg) g
Stable h 10 140 1.00 1.00
Gain, 3.0-9.9 31 291 1.38 0.65-2.93 1.47 0.69-3.16
Gain, 10.0-19.9 42 376 1.31 0.63-2.72 1.67 0.76-3.65
Gain, ≥20.0 39 401 1.05 0.50-2.19 1.45 0.60-3.48
P trend = 0.63 P trend = 0.48
Waist (cm) e
T1: ≤ 85.0 28 385 1.00 1.00
T2: 85.1-96.4 40 407 1.13 0.67-1.89 1.43 0.80-5.54
T3: >96.4 48 412 1.24 0.75-2.06 1.87 0.96-3.64
P trend = 0.41 P trend = 0.07
Hip (cm) e
T1: ≤ 102.9 27 394 1.00 1.00
T2: 103.0-112.7 41 402 1.40 0.84-2.34 1.85 1.05-3.28
T3: >112.7 48 407 1.43 0.86-2.37 2.35 1.20-4.59
P trend = 0.19 P trend = 0.01
Waist-to-hip ratio
T1: ≤ 0.81 33 434 1.00 1.00
T2: 0.82-0.86 34 355 1.14 0.68-1.90 1.21 0.72-2.04
T3: >0.86 49 413 1.35 0.83-2.18 1.46 0.88-2.39
P trend = 0.22 P trend = 0.14
Waist-to-height ratio
T1: ≤ 0.54 30 372 1.00 1.00
T2: 0.55-0.61 40 410 0.98 0.59-1.63 1.19 0.66-2.17
T3: >0.61 46 422 1.05 0.63-1.73 1.44 0.72-2.87
P trend = 0.84 P trend = 0.30
Abbreviations: BMI, body mass index; CI, confidence interval; ER-, estrogen receptor–negative; OR, odds ratio; PR-, progesterone receptor–negative.
a OR and 95% CI adjusted for age (years, continuous), race/ethnicity (non-Hispanic White, African American, Hispanic), place of birth (US-born, foreign-born), age at
menarche (≤11, 12, 13, ≥14 years), and lifetime breast-feeding (nulliparous, 0, ≤6, 7–12, 13–24, ≥25 months).
b Adjusted for above variables, and current BMI.
c Adjusted for above variables, and weight gain.
d Based on self-reported weight and measured height at interview (if not available, then based on measured weight at interview and/or self-reported height).
e Based on tertiles among all postmenopausal controls.
f Based on self-reported young-adult weight and measured height at interview (or self-reported adult height when measured height not available).
g Self-reported weight (or measured weight at interview if self-reported weight not available) minus self-reported young-adult weight; excludes 5 cases and 55
controls who lost >3 kg of weight
h Stable weight defined as +/− 3 kg.
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2005; Palmer et al. 2007), only one found a significant
association with BC risk overall (White et al. 2012). In
Hispanic women from New Mexico, large weight gain was
associated with a two-fold increased risk of ER+PR+ disease
and, for BC overall, a significant trend with weight gain
was limited to women with a BMI <22 kg/m2 at age 18
years (Wenten et al. 2002). Two other studies in Hispanics
found no association with weight gain (Slattery et al. 2007;
White et al. 2012). In order to address these inconsistent
findings with BMI and weight gain for AA and Hispanic
women, future studies should examine the modifying
effect of young-adult obesity with larger sample sizes.
This is particularly important since AA and Hispanic
women have a higher prevalence of young-adult obesity
than NHWs, as found in our study as well as others
(Flegal et al. 2010).
Our finding of a strong inverse association of postmeno-
pausal BC risk with high young-adult BMI, which was
independent of weight change or current BMI, is consistent
with other reports (White et al. 2012; Palmer et al. 2007;
Berstad et al. 2010; Barnes-Josiah et al. 1995; Huang et al.
1997; Morimoto et al. 2002; Ahn et al. 2007; Chu et al.
1991; Brinton & Swanson 1992; Magnusson et al. 1998),
although in some studies there was no association with
young-adult BMI (Canchola et al. 2012; Feigelson et al.
2004; Lahmann et al. 2005). In agreement with a large
meta-analysis (Suzuki et al. 2009), we found that the
inverse association with young-adult BMI did not differ by
tumor hormone receptor status. We further found an
inverse association, regardless of HT use, as reported by
others (Morimoto et al. 2002; Ahn et al. 2007). These
findings do not support an estrogen-related mechanism
underlying the association with young-adult BMI.
Abdominal adiposity has been proposed to be more
important in estrogen production than adiposity at other
body sites (Pinheiro et al. 2009). Studies in primarily
NHW women, however, have produced inconsistent
results (World Cancer Research Fund / American Institute
for Cancer Research 2007). Not all studies considered HT
use or ER/PR status, or adjusted for overall adiposity
(Canchola et al. 2012; Potter et al. 1995; Huang et al.
2000). Our findings confirm previous reports of positive
associations with waist circumference and WHtR only in
women not currently using HT (Morimoto et al. 2002;
Huang et al. 1999; Friedenreich et al. 2002) and stronger
associations for ER+PR+ disease (Canchola et al. 2012;
Potter et al. 1995; Huang et al. 2000). We found no associ-
ation with WHR, whereas elevated WHtR was associated
with increased risk, in agreement with another study
(Canchola et al. 2012). Both waist circumference and
WHtR may be better measures of abdominal adiposity
than WHR (Molarius & Seidell 1998; Rankinen et al. 1999).
In some studies, the association with abdominal adipositywas attenuated after adjustment for BMI (Morimoto et al.
2002; Lahmann et al. 2004; Tehard & Clavel-Chapelon
2006), whereas in our study associations became
stronger after BMI-adjustment. Among women with
BMI <25 kg/m2, large waist circumference and high
WHtR were associated with two-fold increased risks of
BC overall. Contrary to another study that reported an
association between abdominal adiposity and ER+PR+
tumors only in normal-weight women (Canchola et al.
2012), we found elevated ORs for ER+PR+ tumors,
regardless of BMI, with statistically significant estimates in
overweight/obese women.
Unlike NHW women, for whom we found no associations
with waist circumference and WHtR, AAs and Hispanics
had two- to three-fold increased risk of ER+PR+ BC. We
found no association with WHR in any racial/ethnic
group. This latter finding is consistent with two studies in
AA women (Hall et al. 2000; Palmer et al. 2007), but
contrasts with reports from Nigeria (Ogundiran et al.
2010) and Barbados (Nemesure et al. 2009), where large
waist circumference and high WHR increased BC risk.
Similarly, the two-fold increased risk of ER+PR+ disease
associated with large hip circumference that we observed
for NHW and Hispanic women was not seen in AAs,
whereas previous studies from Nigeria (Ogundiran et al.
2012) and Barbados (Nemesure et al. 2009) reported
inverse associations with hip circumference. In the Nigerian
study, associations with abdominal adiposity were stronger
or limited to women with a BMI <25 kg/m2 (Ogundiran
et al. 2012), consistent with our findings. In the only study
that examined abdominal adiposity in postmenopausal
Hispanic women, hip circumference and WHR were not
associated with BC risk in not recent HT users (Slattery
et al. 2007), which differs from our finding. Given these
conflicting reports, it remains to be determined whether
there are true racial/ethnic differences in the effects of
abdominal adiposity on BC risk. Abdominal fat comprises
different fat stores, and AAs and NHWs differ in
abdominal depot-specific body fat (e.g., visceral vs.
subcutaneous adipose tissue) (Katzmarzyk et al. 2010).
Whether different fat stores affect BC risk differentially
has not been examined. Our results suggest that studies
should assess multiple measures of adiposity in racially/
ethnically diverse populations.
Our analyses of body size and ER-PR- BC risk were
limited by small numbers. Consistent with most other
studies (Suzuki et al. 2009; Yang et al. 2011), we found
no associations with current BMI and weight gain, although
there are some reports of inverse (Berstad et al. 2010;
Setiawan et al. 2009) or positive associations with BMI
(Ritte et al. 2012) and positive associations with weight
gain (Canchola et al. 2012). Unlike other studies
(Canchola et al. 2012; Potter et al. 1995), we found a
strong inverse association with young-adult BMI and
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positive association between waist (Ptrend = 0.07) and hip
(Ptrend = 0.01) circumferences and risk of ER-PR- BC, but,
consistent with other studies (Canchola et al. 2012; Potter
et al. 1995; Huang et al. 2000), we found no significant
association with WHR or WHtR. The association between
BMI, weight gain, and abdominal adiposity warrants further
examination in studies with larger numbers of ER-PR-
cases. This is particularly important since few risk factors
have been identified for hormone receptor negative BC
(Althuis et al. 2004; Ma et al. 2006), which disproportion-
ately affects AA and Hispanic women (Ray & Polite 2010).
Our findings should be considered in light of some
limitations. Due to the concern that weight may be
impacted by BC diagnosis and treatment, we relied on
self-reported weight during the reference year. Although
we cannot exclude the possibility of inaccurately recalled
weight, among subjects for whom measured and self-
reported weight was available, the correlation between
the two measures was high (r = 0.85 for cases, r = 0.92
for controls). For waist and hip circumference we had to
rely on measurements taken after diagnosis which may
have also resulted in misclassification. Finally, some sub-
group analyses were limited by small sample sizes, and
analyses of potential modifying factors (young-adult BMI,
time since menopause) could not be further stratified by
race/ethnicity. Larger studies or analyses of pooled data
will be necessary to further explore the role of these
modifying factors in Hispanics and AAs.
Our study also has several important strengths, including
a population-based design, high participation rates among
cases and controls in each racial/ethnic group, assessment
of both overall and abdominal adiposity, detailed data
on established BC risk factors, and availability of data
on tumor hormone receptor status for most cases. The
racial/ethnic diversity of the study population allowed
us to assess associations with body size in Hispanic and
AA women, thus contributing to the relatively sparse
data in these two racial/ethnic populations that experience
a greater burden of obesity than NHWs.
It has been estimated that as many as one third of new
postmenopausal BC cases may be attributable to adult
weight gain (Huang et al. 1997). Given that a number of
BC risk factors relate to events well before menopause (e.g.,
age at menarche, age at first birth) or characteristics that
cannot easily be modified (e.g., BC family history), observed
associations with body size suggest possible approaches to
lowering BC risk in older women through weight main-
tenance, avoidance of further weight gain and abdominal
adiposity, or weight loss. However, promoting overweight
at a young age, as a means of reducing BC risk after
menopause, should not be encouraged, given the many
adverse health effects associated with obesity, including
other cancers (Calle & Kaaks 2004; Chen et al. 2011).Abbreviations
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